Real-time · AI · Cross-signal
Passage Bio just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on Passage Bio, plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration
Aug 01, 2024•almost 2 years ago
Contract Type
partnership
United StatesBiotechnologyHealthcareHealth CareGeneticsTherapeuticsDescription
Passage Bio, Inc. has out-licensed its three clinical-stage pediatric lysosomal storage disease programs to GEMMA Biotherapeutics, Inc. and entered a new strategic research and collaboration agreement to advance genetic medicines for CNS indications, extending the operating cash runway to the end of Q2 2026.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months